Company Overview
TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in two segments, Financial Health and Patient Care. It offers revenue cycle management (RCM) products, including patient liability estimate, eligibility verification, claim scrubbing and submission, remittance management, denial/audit management, and contract management services; RCM services, such as accounts receivable management, private pay service, medical coding, revenue cycle consulting, and other additional insurance and patient billing services; consulting, business intelligence, staffing, and administrative services; cloud services, backup and recovery, collaboration and connectivity, security services, systems management, and help desk services; and encoder solutions. The company also provides TruBridge HER, a software solution platform which offers various software applications using one fully integrated system designed to streamline the flow of information to the primary functional areas of community hospitals. In addition, it offers acute care support and maintenance services comprising total system support, national client conference, continuing education, software releases, hardware replacement, cloud electronic health record, forms and supplies, instantPHR, and CHBase. Further, the company provides business management services; acute care EHR solutions and related services for community hospitals, and their physician clinics; and patient engagement and technology solutions. The company was formerly known as Computer Programs and Systems, Inc. and changed its name to TruBridge, Inc. in March 2024. TruBridge, Inc. was founded in 1979 and is headquartered in Mobile, Alabama. As of July 9, 2026, TruBridge, Inc. operates as a subsidiary of Inventurus Knowledge Solutions Limited.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $346.84M (+1.4% YoY); net profit $4.35M.
- Trailing 12 Months Year-on-year growth — revenue -1.1%, earnings +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.0%, profit CAGR -35.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.02% |
| 1 Year: | -1.10% |
Compounded Profit Growth
| 5 Years: | -35.02% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | +19.65% |
| 6 Months: | +15.59% |
| 3 Months: | +45.94% |
| 1 Month: | +0.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)79.10 · Overbought
P/E of 90.48 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 90.5.
- Earnings shrank at -35.0% CAGR over 5 years.
- RSI at 79 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TBRG TruBridge, Inc. R2K | 26.24 | 90.48 | $393.58M | 0.00% | 4.70% | 2.54% | 2.02% | -35.02% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 64.08M | 67.68M | 67.11M | 78.06M | 70.88M | 67.91M | 69.30M | 72.33M | 69.14M | 66.16M | 68.70M | 70.64M | 69.76M | 59.55M | 68.33M | 66.85M | 68.00M | 68.53M | 70.09M | 77.87M | 82.73M | 82.83M | 86.23M | 84.62M | 82.71M | 84.12M | 85.60M | 84.70M | 87.21M | 85.73M | 86.11M | 87.79M | 86.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.51M | 41.27M | 42.05M | 40.14M | 38.35M |
| Gross Profit | 24.71M | 22.73M | 22.57M | 36.09M | 34.91M | 32.77M | 33.49M | 32.70M | 35.99M | 34.38M | 44.20M | 39.09M | 34.85M | 36.11M | 39.68M | 37.12M | 34.53M | 35.91M | 36.58M | 36.11M | 30.11M | 35.42M | 34.61M | 34.85M | 33.89M | 35.29M | 41.19M | 40.67M | 38.02M | 42.06M | 40.49M | - | - | - | - | 47.70M | 44.46M | 44.06M | 47.65M | 47.92M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.53M | 40.83M | 39.99M | 42.67M | 44.87M |
| Operating Income | 8.39M | 4.26M | 4.61M | 776.00K | 5.26M | 4.24M | 4.09M | 3.23M | 4.45M | 5.62M | -18.12M | 7.65M | 2.23M | 5.36M | 9.65M | 6.05M | 3.62M | 6.01M | 8.91M | 6.13M | 2.75M | 6.20M | 5.97M | 4.91M | 7.74M | 4.53M | 8.99M | 4.59M | 4.94M | 6.29M | -1.91M | -5.21M | -588.00K | -2.15M | 2.81M | 8.16M | 3.63M | 4.07M | 4.98M | 3.06M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.72M | 10.37M | 11.09M | 6.29M | 10.08M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.38M | 3.06M | 3.00M | 2.87M | 2.63M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.92M | 698.00K | 1.35M | -3.10M | 582.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.46M | -1.88M | -4.25M | 1.19M | 76.00K |
| Net Income | 5.90M | 3.54M | 3.39M | -1.66M | 2.00M | 1.60M | 2.00M | 246.00K | 1.59M | 2.29M | -21.54M | 3.97M | 328.00K | 5.75M | 7.59M | 3.44M | 1.66M | 4.13M | 11.23M | 4.09M | 1.76M | 5.27M | 3.12M | 4.14M | 6.14M | 2.74M | 8.11M | 3.08M | 2.16M | 3.08M | -2.84M | -3.56M | -1.85M | -4.39M | -9.15M | 459.00K | 2.58M | 5.60M | -4.29M | 506.00K |
| Diluted EPS | 0.52 | 0.31 | 0.30 | -0.13 | 0.15 | 0.12 | 0.15 | 0.02 | 0.11 | 0.17 | -1.57 | 0.29 | 0.02 | 0.41 | 0.54 | 0.24 | 0.12 | 0.29 | 0.78 | 0.28 | 0.12 | 0.36 | 0.22 | 0.28 | 0.42 | 0.19 | 0.55 | 0.21 | 0.15 | 0.21 | -0.20 | -0.24 | -0.13 | -0.29 | -0.61 | 0.03 | 0.17 | 0.37 | -0.37 | 0.03 |
| R&D Expense | 3.57M | 3.56M | - | 7.19M | 8.18M | 8.40M | - | 8.08M | 8.41M | 8.25M | - | 8.76M | 9.31M | 9.30M | - | 9.23M | 9.30M | 9.16M | - | 8.27M | 8.37M | 8.55M | - | 8.43M | 6.47M | 7.70M | 8.06M | 8.11M | 7.99M | 8.35M | 8.77M | 9.78M | 10.69M | 8.21M | 7.74M | 8.25M | 8.11M | 8.17M | - | 7.45M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.74M | 153.25M | 173.48M | 183.31M | 200.86M | 204.74M | 182.17M | 267.27M | 276.93M | 280.41M | 274.63M | 264.49M | - | 326.65M | 336.96M | 342.20M | 346.84M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 166.54M | 175.56M | 168.92M | 162.97M |
| Gross Profit | 53.26M | 64.38M | 79.41M | 80.66M | 93.74M | 113.95M | 94.46M | 133.73M | 147.27M | 149.73M | 144.15M | 136.25M | - | 160.11M | 161.40M | 173.28M | 183.86M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.32M | 168.83M | 166.91M | 163.03M |
| Operating Income | 23.37M | 29.10M | 41.29M | 41.28M | 50.24M | 49.59M | 25.09M | 14.38M | -4.81M | 24.88M | 24.58M | 21.05M | - | 22.78M | -7.43M | 6.37M | 20.83M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.73M | -18.62M | 34.27M | 42.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.32M | 12.52M | 16.17M | 12.32M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.08M | -57.46M | -10.47M | 3.87M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.21M | -9.33M | 10.48M | -485.00K |
| Net Income | 15.18M | 18.74M | 25.83M | 29.97M | 32.74M | 32.92M | 18.34M | 3.93M | -17.42M | 17.63M | 20.47M | 14.25M | - | 15.87M | -48.13M | -20.95M | 4.35M |
| Diluted EPS | 1.39 | 1.71 | 2.34 | 2.71 | 2.95 | 2.94 | 1.62 | 0.29 | -1.27 | 1.26 | 1.43 | 0.98 | - | 1.08 | -3.15 | -1.55 | 0.29 |
| R&D Expense | - | 2.33M | 2.45M | 2.76M | 2.76M | 14.62M | 14.23M | 29.09M | 33.74M | 36.37M | 36.86M | 33.46M | 32.81M | 31.90M | 38.83M | 35.45M | 32.56M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.74M | 75.64M | 77.09M | 92.53M | 99.32M | 92.79M | 339.15M | 318.22M | 327.75M | 339.59M | 326.27M | - | 430.96M | 431.78M | 395.82M | 402.53M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.56M | 108.81M | 93.69M | 104.64M |
| Cash & Equivalents | 11.74M | 4.39M | 2.94M | 6.66M | 8.91M | 11.73M | 23.79M | 24.95M | 2.22M | 520.00K | 5.73M | 7.36M | 12.67M | - | 6.95M | 3.85M | 12.32M | 24.85M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 784.00K | 475.00K | 767.00K | 623.00K |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.31M | 56.24M | 52.95M | 54.97M |
| Total Liabilities | - | - | - | - | - | - | - | 17.42M | 181.18M | 182.13M | 167.96M | 155.24M | 126.27M | - | 199.25M | 247.80M | 228.75M | 224.57M |
| Current Liabilities | - | - | 14.49M | 16.67M | 17.72M | 21.45M | 18.16M | 17.42M | 30.95M | 40.85M | 38.50M | 41.93M | 37.44M | - | 44.45M | 48.23M | 56.00M | 57.96M |
| Long Term Debt | - | - | - | - | - | - | - | 0 | 146.99M | 136.61M | 124.58M | 99.43M | 73.36M | - | 136.39M | 195.27M | 168.60M | 161.24M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.24M | 203.29M | 174.81M | 166.74M |
| Total Equity | 40.56M | 42.69M | 46.46M | 57.38M | 57.20M | 69.08M | 80.78M | 75.37M | 157.97M | 136.09M | 159.78M | 184.35M | 200.00M | - | 231.71M | 183.97M | 167.07M | 177.96M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.91M | 15.12M | 15.52M | 15.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 8.81M | 19.64M | 33.54M | 32.21M | 29.05M | 38.95M | 30.88M | 2.10M | 23.64M | 23.93M | 43.60M | 49.14M | - | 32.38M | -522.00K | 31.14M | 36.97M |
| Investing Cash Flow | -2.16M | -5.31M | -14.03M | 1.48M | -3.68M | -1.52M | -598.00K | -151.79M | -726.00K | -978.00K | -12.49M | -6.66M | - | -62.73M | -58.53M | 5.12M | -14.72M |
| Financing Cash Flow | -14.01M | -15.78M | -15.79M | -31.44M | -22.55M | -25.36M | -29.12M | 126.95M | -24.62M | -17.74M | -29.48M | -37.16M | - | 25.88M | 55.95M | -27.74M | -9.71M |
| Capital Expenditure | -829.10K | -5.09M | -10.85M | -4.36M | -3.63M | -1.47M | -448.00K | -39.00K | -726.00K | -978.00K | -1.76M | -3.34M | - | -19.37M | -21.82M | -18.11M | -17.13M |
| Free Cash Flow | 7.98M | 14.55M | 22.69M | 27.84M | 25.42M | 37.48M | 30.43M | 2.07M | 22.92M | 22.95M | 41.84M | 45.81M | - | 13.01M | -22.35M | 13.04M | 19.84M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.48M | -3.10M | 8.52M | 12.53M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | 0 | 0 | 1.26M | 1.31M | 11.92M | 2.58M | 404.00K | 1.95M |
| Dividends Paid | 15.77M | 15.79M | 15.89M | 31.44M | 22.64M | 25.53M | 28.94M | 25.09M | 11.64M | 5.62M | 5.73M | 4.34M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 41.7% | 42.0% | 45.8% | 44.0% | 46.7% | 55.7% | 51.9% | 50.0% | 53.2% | 53.4% | 52.5% | 51.5% | - | 49.0% | 47.9% | 50.6% | 53.0% |
| Operating Margin % | 18.3% | 19.0% | 23.8% | 22.5% | 25.0% | 24.2% | 13.8% | 5.4% | -1.7% | 8.9% | 9.0% | 8.0% | - | 7.0% | -2.2% | 1.9% | 6.0% |
| Net Margin % | 11.9% | 12.2% | 14.9% | 16.4% | 16.3% | 16.1% | 10.1% | 1.5% | -6.3% | 6.3% | 7.5% | 5.4% | - | 4.9% | -14.3% | -6.1% | 1.3% |
| ROE % | 35.6% | 40.3% | 45.0% | 52.4% | 47.4% | 40.8% | 24.3% | 2.5% | -12.8% | 11.0% | 11.1% | 7.1% | - | 6.8% | -26.2% | -12.5% | 2.4% |
| ROCE % | - | 60.3% | 70.0% | 69.5% | 70.7% | 61.1% | 33.3% | 4.7% | -1.7% | 8.6% | 8.3% | 7.3% | - | 5.9% | -1.9% | 1.9% | 6.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nellore Capital Management LLC | 6.59% | 988.45K | $25.94M |
| 2 | Blackrock Inc. | 4.89% | 732.87K | $19.23M |
| 3 | Vanguard Capital Management LLC | 3.85% | 577.38K | $15.15M |
| 4 | Dimensional Fund Advisors LP | 3.75% | 562.85K | $14.77M |
| 5 | MARTIN & CO INC /TN/ | 2.99% | 448.65K | $11.77M |
| 6 | Ameriprise Financial, Inc. | 1.97% | 295.48K | $7.75M |
| 7 | Federated Hermes, Inc. | 1.95% | 292.41K | $7.67M |
| 8 | Kennedy Capital Management, LLC | 1.89% | 283.84K | $7.45M |
| 9 | Geode Capital Management, LLC | 1.67% | 250.97K | $6.59M |
| 10 | State Street Corporation | 1.30% | 195.22K | $5.12M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TBRG
TruBridge (TBRG) Stock Gets Fair Value Boost As Analysts Weigh IKS Deal Risks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOM085WWpBTmFNd2ZHRVNLbjlhNTlWUEVEbmswaC1Rdk55aDc3Z1dIMzVaN3o2SW9WX2VyZ2UweFVpUzZiaklBdTdsdWFhaWRKUXZKZTJCSXBIbzhqUW9zU05kdFFRZXlEaDVIVkc4LTBuQWRNTDdKNklZRUFpSHJIOTkzazlBVnBOOXJMMT…
[Form 4] TruBridge, Inc. Insider Trading Activity - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNQU9GOHZoTWpuMnVSaG5qakhFSW5PXzlkUzAtQzNVNXJfd09mVGdiME5wMWMwczNCZzZEZUNNU25mRFd4UkQ1VHk1MElLRGhQZXNLWHFieXF0djM2Y2MwMW9pQkZRSlVrbmF0cDJsbHNFRFBnNFA4enNlMjIyRkRxaExKTFFFS3BDblNxSm…
TruBridge (TBRG) officer logs stock dispositions as $26.25-per-share cash merger closes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNQ1hQa1FMTk9nS3J2bUZpUl82Ykowb3YyMjZLUkV2cXpOa2xlZHJfMm4xZWMyOFRnQnhrdllpeWd1UjJsRmdkZUFpdkJSUWRQU1FkWXkxVFBMTHpwaXV2eGpEQm9BZmpueHZlbFZ5dFd4X2NNQkFETlMyNERNODd4SWV1bGNha1JIM2hUMG…
TruBridge (TBRG) Controller reports merger-related stock forfeiture and $26.25 cash-out - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNTWpSWDBpTk1FVDVpNTdjTUp1QzdVanM2VWRFNnFEUnBhZExEQkF0bE8zSTh4SnNhTmdWRktPWElXem5KQTZ0eThWd1RtUVlRaFc4aV9BUmV1ZTBnODBGb2UzdW8zTmJLNDgyaDc3ZGZxeVVWemJoT0VzUE5lVzBfNFR0bkIyaVBibl92Z0…
TruBridge (TBRG) director’s 38,687 shares cancelled in $26.25-per-share cash merger - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQWVhYb0EyZGZacGtobTBzS1RQa01jRUk5Y3hvM3owbDQ1MFJwZ0xmRS1SNnZwekRpb3N3bGxpcENpVkp4R2o2eFM5UFM0WC13ZHBSblZpN1ZIQV9tVmtZWXhnUFM0LXRGelBjQVh5YVpFQzlaOC0tdlROc2hCb2tBYVBYTG1naWtFc1l0ZF…
TruBridge (TBRG) director fully cashes out common stock at $26.25 per share in merger - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOZldwcjFkcExvZlNIMFJ1eVdueldWVXBqamR4Y19uVXBKakNYV2pYa0R6ekI4M0JpLVFPWjdKOFBKWUpzM0stTlptQ3ptRlNiOVRyQldXNEU1WGxmOHlhRC1QbTNaZ1pMT3pmNzRoWHBxdDVvMDkxXzFjMWFpdjloQllobERVRjlxWE1tRU…
TBRG — Frequently Asked Questions
What is the current share price of TruBridge, Inc. (TBRG)?
As of 2026-07-14 21:23 PDT, TruBridge, Inc. (TBRG) trades at $26.24 on NasdaqGS. Its 52-week range is $14.00 to $26.25.
What is the market capitalisation of TBRG?
TruBridge, Inc. (TBRG) has a market capitalisation of $393.58M on NasdaqGS.
What is the P/E ratio of TBRG?
TBRG trades at a trailing price-to-earnings (P/E) ratio of 90.48. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.16.
What is the return on equity (ROE) of TBRG?
TBRG has a return on equity (ROE) of 2.54%. Its return on capital employed (ROCE) is 4.70%.
Is TBRG a good stock to buy?
This page provides a data-driven analysis of TruBridge, Inc. (TBRG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.